Jobs
-
According to Impel NeuroPharma, a Phase 1 proof-of-concept trial of its INP104 intranasal dihydroergotamine (DHE) for the treatment of acute migraine headache demonstrated comparable bioavailability for INP104 to IV DHE and a statistically significant increase… Read more . . .
-
Trudell Medical International has announced publication of a retrospective study that found a 13% reduction in emergency room visits for patients using a metered dose inhaler with the company’s AeroChamber Plus Flow-Vu Anti-Static valved holding… Read more . . .
-
Liquidia Technologies, which recently published positive Phase 1 results for its LIQ861 treprostinil DPI for the treatment of pulmonary arterial hypertension, has named former Quintiles executive Kevin Gordon as President and Chief Financial Officer. Gordon… Read more . . .
-
OINDP testing specialist Proveris Scientific Corporation has announced the appointment of Chip Leveille as President, effective immediately. Leveille had been the Chief Commercial Officer at the company since April 2016 and previously held positions at… Read more . . .
-
The upcoming RDD 2018 meeting, which will take place April 22-26 in Tucson, AZ, features a program designed to address many of the most pressing questions for OINDP developers today, along with extensive poster and… Read more . . .
-
The FDA has granted orphan drug designation to Dauntless Pharmaceuticals’ DP1038 intranasal octreotide acetate for the treatment of acromegaly, the company said. Dauntless announced positive Phase 1 results for DP1038 in May 2015. Dauntless Pharmaceuticals… Read more . . .
-
AstraZeneca has announced top-line results from the Phase 3 KRONOS trial of its PT010 budesonide/glycopyrronium/formoterol fumarate MDI for the treatment of moderate to severe COPD. Compared to Bevespi Aerosphere glycopyrronium/formoterol fumarate, Symbicort Turbuhaler budesonide/formoterol fumarate,… Read more . . .
-
Theravance Biopharma and Mylan have announced that the NDA for revefenacin (TD-4208) inhalation solution for the treatment of COPD the companies submitted in November 2017 has been accepted for review by the FDA, with a… Read more . . .
-
Aradigm Corporation has received a complete response letter from the FDA in response to its NDA for Linhaliq dual release inhaled ciprofloxacinfor the treatment of P. aeruginosa infections in non-cystic fibrosis bronchiectasis (NCFBE) patients, the… Read more . . .
-
According to GlaxoSmithKline and Innoviva, the EMA’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion regarding approval of the Relvar Ellipta fluticasone furoate/vilanterol DPI for the treatment of asthma that… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland